A Phase 3 interventional study of aflibercept and bevacizumab in Central Retinal Vein Occlusion, sponsored by The Emmes Company, LLC. Completed at 72 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-22.
Sponsored by The Emmes Company, LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing aflibercept in Retinal Vein Occlusion — none open to participants now, none under way, none of them phase 3. aflibercept · Retinal Vein Occlusion.
Among the 21 studies testing aflibercept in Retinal Vein Occlusion, this one has the largest enrollment, is one of 3 that started in 2014, is one of 4 in phase 3, and was the 7th registered.
289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.
Browse Retinal Vein Occlusion studies →None of the 21 studies testing aflibercept in Retinal Vein Occlusion is open now. The open studies under Retinal Vein Occlusion, anywhere →
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 4 · Phase 4 10
First in 2009; this study’s year is marked. 3 started in 2014.
This study's enrollment of 362 is above the median of 51 across 208 interventional studies indexed under Retinal Vein Occlusion.
Median enrollment 56 across the 21 interventional studies. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 21 have an industry lead sponsor. The 10 most frequent:
The Emmes Company, LLC is the lead sponsor of 11 studies on the registry; none are open to participants now.
The Emmes Company, LLC has 3 studies filed under Retinal Vein Occlusion — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing aflibercept in Retinal Vein Occlusion, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
SCORE2 is a multicenter, prospective, randomized, phase III clinical trial in which all participants enrolled will be followed for up to 2.5 years. SCORE2 is designed as a non-inferiority trial, with study eyes randomized to intravitreal bevacizumab (1.25 mg) every 4 weeks vs. intravitreal aflibercept (2.0 mg) every 4 weeks. SCORE2 aims to determine if bevacizumab is non-inferior to aflibercept for the treatment of macular edema associated with central retinal vein occlusion (CRVO), with the primary outcome of visual acuity measured at Month 6.
The primary objective of SCORE2 is to test for non-inferiority based on mean change from baseline in visual acuity letter score at Month 6 for eyes randomized to intravitreal bevacizumab every 4 weeks compared with eyes randomized to intravitreal aflibercept every 4 weeks using a non-inferiority margin of 5 letters.
Secondary objectives of SCORE2 are to:
Other exploratory aims of SCORE2 are to:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2.0 mg aflibercept every 4 weeks
Drug: aflibercept
1.25 mg bevacizumab every 4 weeks
Drug: bevacizumab
Also known as: EYLEA
Also known as: Avastin
Mean Change From Baseline in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Letter Score at Month 6
The primary analysis is based on observed data at 6 months. The measure is calculated by subtracting the baseline visual acuity letter score from the month 6 visual acuity letter score. The participant is refracted for best corrected vision, and then reads single letters on an electronic visual acuity tester at a 3 meter distance according to a specific algorithm. A letter score is provided that ranges from 0 (unable to ready any letters) to 100. A visual acuity letter score of 85 corresponds to a visual acuity of 20/20 as a Snellen equivalent.
Time frame: Month 0 to 6
Number of Study Eyes With Gain of ≥15 Letters in Visual Acuity Letter Score at Month 6
The measure is the number of study eyes that gained at least 15 letters in their visual acuity letter score at month 6
Time frame: Month 0 to 6
Number of Study Eyes With Visual Acuity Letter Score of 70 or Better at Month 6
The measure is the number of study eyes with a visual acuity letter score of 70 (Snellen equivalent of 20/40) or better at month 6
Time frame: Month 0 to 6
Mean Spectral-domain Optical Coherence Tomography Central Subfield Thickness
The measure is the mean central subfield thickness at month 6 measured by spectral-domain optical coherence tomography
Time frame: Month 0 to 6
Mean Change From Baseline in Spectral Domain Optical Coherence Tomography Central Subfield Thickness at Month 6
The measure is calculated by subtracting the baseline central subfield thickness from the month 6 central subfield thickness
Time frame: Month 0 to 6
Number of Study Eyes With Central Subfield Thickness <300 μm, no Subretinal Fluid, no Intraretinal Fluid, and no Cystoid Spaces
The measure is the number of study eyes with central subfield thickness \<300 μm, no subretinal fluid, no intraretinal fluid, and no cystoid spaces at month 6
Time frame: Month 0 to 6
The SCORE2 randomized noninferiority clinical trial was conducted at 66 private practice or academic centers in the United States, and included 362 patients with macular edema due to central retinal or hemiretinal vein occlusion who were randomized 1:1 to receive aflibercept or bevacizumab.
| Milestone | Aflibercept | Bevacizumab |
|---|---|---|
| Started | 180 | 182 |
| Completed | 175 | 173 |
| Not completed | 5 | 9 |
The primary analysis is based on observed data at 6 months. The measure is calculated by subtracting the baseline visual acuity letter score from the month 6 visual acuity letter score. The participant is refracted for best corrected vision, and then reads single letters on an electronic visual acuity tester at a 3 meter distance according to a specific algorithm. A letter score is provided that ranges from 0 (unable to ready any letters) to 100. A visual acuity letter score of 85 corresponds to a visual acuity of 20/20 as a Snellen equivalent.
| letters read | Aflibercept | Bevacizumab |
|---|---|---|
| Mean Change From Baseline in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Letter Score at Month 6 | 18.9 (16.62 to 21.15) | 18.6 (16.16 to 21.09) |
The measure is the number of study eyes that gained at least 15 letters in their visual acuity letter score at month 6
| study eyes | Aflibercept | Bevacizumab |
|---|---|---|
| Number of Study Eyes With Gain of ≥15 Letters in Visual Acuity Letter Score at Month 6 | 114 | 106 |
The measure is the number of study eyes with a visual acuity letter score of 70 (Snellen equivalent of 20/40) or better at month 6
| study eyes | Aflibercept | Bevacizumab |
|---|---|---|
| Number of Study Eyes With Visual Acuity Letter Score of 70 or Better at Month 6 | 101 | 99 |
The measure is the mean central subfield thickness at month 6 measured by spectral-domain optical coherence tomography
| um | Aflibercept | Bevacizumab |
|---|---|---|
| Mean Spectral-domain Optical Coherence Tomography Central Subfield Thickness | 231.3 (220.8 to 241.8) | 287.9 (269.4 to 306.4) |
The measure is calculated by subtracting the baseline central subfield thickness from the month 6 central subfield thickness
| um | Aflibercept | Bevacizumab |
|---|---|---|
| Mean Change From Baseline in Spectral Domain Optical Coherence Tomography Central Subfield Thickness at Month 6 | -425 (-461 to -389) | -387 (-426 to -348) |
The measure is the number of study eyes with central subfield thickness \<300 μm, no subretinal fluid, no intraretinal fluid, and no cystoid spaces at month 6
| study eyes | Aflibercept | Bevacizumab |
|---|---|---|
| Number of Study Eyes With Central Subfield Thickness <300 μm, no Subretinal Fluid, no Intraretinal Fluid, and no Cystoid Spaces | 92 | 49 |
Collected over Month 0 to 6. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aflibercept | 1/180 (0.6%) | 14/180 (7.8%) | 82/180 (45.6%) |
| Bevacizumab | 1/182 (0.5%) | 14/182 (7.7%) | 98/182 (53.8%) |
| Event | Aflibercept | Bevacizumab |
|---|---|---|
| PneumoniaInfections and infestations | 0/180 | 2/182 |
| Acute kidney injuryRenal and urinary disorders | 1/180 | 0/182 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/180 | 0/182 |
| Ankle fractureInjury, poisoning and procedural complications | 1/180 | 0/182 |
| ArthritisMusculoskeletal and connective tissue disorders | 1/180 | 0/182 |
| BronchitisInfections and infestations | 1/180 | 0/182 |
| Cardiac failure congestiveCardiac disorders | 1/180 | 0/182 |
| Cerebrovascular accidentNervous system disorders | 1/180 | 0/182 |
| Diabetic foot infectionInfections and infestations | 1/180 | 0/182 |
| Escherichia infectionInfections and infestations | 1/180 | 0/182 |
| Event | Aflibercept | Bevacizumab |
|---|---|---|
| Conjunctival haemorrhageEye disorders | 4/180 | 14/182 |
| Vitreous floatersEye disorders | 6/180 | 8/182 |
| Visual acuity reducedEye disorders | 3/180 | 7/182 |
| Eye painEye disorders | 6/180 | 3/182 |
| Vitreous detachmentEye disorders | 6/180 | 3/182 |
| HeadacheNervous system disorders | 2/180 | 6/182 |
| NasopharyngitisInfections and infestations | 3/180 | 6/182 |
| Urinary tract infectionInfections and infestations | 3/180 | 6/182 |
| FallInjury, poisoning and procedural complications | 2/180 | 5/182 |
| HypertensionVascular disorders | 3/180 | 5/182 |
| Age, Categorical(Participants) | Aflibercept | Bevacizumab | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 67 | 67 | 134 |
| >=65 years | 113 | 115 | 228 |
| Sex: Female, Male(Participants) | Aflibercept | Bevacizumab | Total |
|---|---|---|---|
| Female | 82 | 75 | 157 |
| Male | 98 | 107 | 205 |
| Ethnicity (NIH/OMB)(Participants) | Aflibercept | Bevacizumab | Total |
|---|---|---|---|
| Hispanic or Latino | 16 | 22 | 38 |
| Not Hispanic or Latino | 164 | 160 | 324 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Aflibercept | Bevacizumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 8 | 2 | 10 |
| Asian | 4 | 2 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 28 | 26 | 54 |
| White | 132 | 146 | 278 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 8 | 6 | 14 |
| Region of Enrollment(participants) | Aflibercept | Bevacizumab | Total |
|---|---|---|---|
| United States | 180 | 182 | 362 |
| Visual Acuity Letter Score (VALS) of Study Eye(letters read) | Aflibercept | Bevacizumab | Total |
|---|---|---|---|
| Mean | 50.3 ± 15.2 | 50.4 ± 15.3 | 50.3 ± 15.2 |
| Time between diagnosis of macular edema and randomization(months) | Aflibercept | Bevacizumab | Total |
|---|---|---|---|
| Mean | 8 ± 17 | 5 ± 10 | 7 ± 14 |
| Spectral Domain-Optical Coherence Tomography (SD-OCT) central subfield thickness(um) | Aflibercept | Bevacizumab | Total |
|---|---|---|---|
| Mean | 652.4 ± 214.6 | 678.2 ± 233.3 | 665.5 ± 224.4 |
10 further baseline measures are reported on the registry.
Plan to share: Yes — SCORE2 will follow specific plans for sharing of research data. After analysis, the final data set can be provided after appropriate procedures are implemented to preserve the anonymity of the records, specifically where protected health information (PHI) is required. Upon request, anonymized data will be shared under confidentiality agreements with researchers interested in the project.
Time frame: The time frame will be determined
Access criteria: Confidentiality agreements will be required before anonymized data will be shared.
Ran from Sep 2014 to primary completion in Nov 2016, 26 months.
Results were first posted in Aug 2018, 1 year 9 months after primary completion.
Of 18 phase 3 interventional studies under Retinal Vein Occlusion, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 26 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aflibercept · Bevacizumab
The Emmes Company, LLC